The HFMA Costing Conference this April highlighted how the role of costing teams across the NHS continues to expand. Throughout the day, discussions reflected the growing reliance on costing insight to support productivity, operational recovery and value‑based decision‑making.
Cost and activity data is being applied far more widely than in the past. It now informs business cases, service reviews, productivity programmes and transformation initiatives, rather than being viewed purely as a regulatory or year‑end exercise. For many organisations, costing insight sits much closer to the centre of both financial and operational conversations.
However, wider use of costing data does not automatically translate into greater confidence in decision‑making. A recurring theme throughout the conference was that while costing models are generally regarded as robust, their outputs are not always seen as sufficiently definitive to resolve complex trade‑offs. This creates a visible gap between the availability of analysis and its ability to carry authority in decision‑making forums beyond finance.
Against this backdrop, the national productivity agenda featured prominently throughout the conference. Speakers emphasised the importance of costing teams in helping organisations move beyond high‑level efficiency narratives towards a more granular understanding of where productivity gains are realistic, sustainable and aligned with patient pathways. There was strong recognition of the contribution costing professionals can make, yet limited clarity on how additional capability, capacity and consistency will be supported at scale.
Several case studies demonstrated the value of linking costing more directly to operational and income considerations. When patient‑level costing is combined with activity volumes and income signals, discussions about productivity become more grounded. Rather than focusing solely on cost reduction, teams are better able to explore value, profitability and service impact in the round. This integrated perspective also helps reframe conversations with clinical and operational leaders, shifting the focus from abstract averages to real pathways and outcomes.
A system‑level perspective added further complexity. Examples showed how pathway‑level changes could generate savings across the NHS while remaining difficult to implement locally. Where the organisation required to invest is not the one that ultimately realises the financial benefit, even well‑evidenced improvements can stall. These dynamics expose the limits of organisation‑level costing insight and reinforce the need for greater visibility across pathways and systems.
Despite the ambition and expertise evident in the room, costing teams were open about what continues to constrain their impact. Capacity pressures remain significant, alongside ongoing challenges related to data quality, coding and timeliness. As a result, costing outputs often require substantial interpretation before they can be used outside finance, making it harder for insights to gain traction and authority across the organisation.
What many participants pointed towards was not a need for more data, but for insight that is quicker to access, easier to explain and trusted across the organisation. Usability, transparency and traceability were consistently highlighted as the conditions under which costing can move beyond informing discussions and begin to decisively shape decisions.
The overarching message from HFMA Costing Conference 2026 was clear. Costing has become a critical capability for understanding productivity and value in a system under sustained pressure. But for that capability to translate into real impact, costing insight must be trusted, usable and able to carry authority beyond finance. Ensuring that costing teams are properly supported in building and sustaining this capability now feels less like an optional enhancement and more like a prerequisite for navigating the years ahead.
